For US Healthcare Professionals Only

Product Information

Learn more about DefenCath, a catheter lock solution proven to reduce the incidence of CRBSIs.1

Find downloadable resources below.

Not Actual Size

DefenCath Prescribing Information

Download the Prescribing Information for DefenCath (taurolidine and heparin) catheter lock solution.

Download

DefenCath Product Flyer

Download the Product Flyer for DefenCath (taurolidine and heparin) catheter lock solution.

Download

DefenCath Magnum Prescribing Information

Download the Prescribing Information for DefenCath (taurolidine and heparin) catheter lock solution.

Download

Agarwal A, et al. 2023 Clin J Am Soc Nephrol.

Access this study publication titled, “Taurolidine/Heparin Lock Solution and Catheter-Related Bloodstream Infection in Hemodialysis: A Randomized, Double-Blind, Active-Control, Phase 3 Study.”

Download

LOCK-IT-100 Overview

Download this digital brochure for a summary of the LOCK-IT-100 trial, which compared DefenCath (taurolidine and heparin) catheter lock solution to the current standard of care.

Download

Product Fact Sheet

Download this resource to learn more about DefenCath (taurolidine and heparin) catheter lock solution.

Download

Product Presentation

Download this presentation to learn more about DefenCath (taurolidine and heparin) catheter lock solution.

Download

FAQ Resource

Download this resource for details on frequently asked questions related to CRBSI’s and DefenCath (taurolidine and heparin) catheter lock solution.

Download

DefenCath Product Ordering Sheet

Download this resource to help navigate the product ordering process.

Download

CRBSI = catheter-related bloodstream infection.

Reference: 1. DefenCath (taurolidine and heparin) [prescribing information]. Berkeley Heights, NJ: CorMedix Inc; 2023.

Expand

Indication and Usage

LIMITED POPULATION: DEFENCATH® is indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis (HD) through a central venous catheter (CVC). This drug is indicated for use in a limited and specific population of patients.

Limitations of Use
The safety and effectiveness of DEFENCATH have not been established for use in populations other than adult patients with kidney failure receiving chronic HD through a CVC.

Important Safety Information

CONTRAINDICATIONS

DEFENCATH is contraindicated in patients with:

  • Known heparin-induced thrombocytopenia (HIT).
  • Known hypersensitivity to taurolidine, heparin or the citrate excipient (components of DEFENCATH), or pork products.

WARNINGS AND PRECAUTIONS

  • Heparin-Induced Thrombocytopenia (HIT): HIT was reported in patients using heparin, a component of DEFENCATH, as a catheter lock solution. If HIT occurs, discontinue DEFENCATH and institute appropriate supportive measures.
  • Drug Hypersensitivity: Drug hypersensitivity reactions have been reported in patients using heparin, a component of DEFENCATH, as a catheter lock solution. If a hypersensitivity reaction occurs, discontinue DEFENCATH and institute appropriate supportive measures.

ADVERSE REACTIONS

The most frequently reported adverse reactions occurring in ≥2% of patients using DefenCath as a CLS were hemodialysis catheter malfunction, hemorrhage/bleeding, nausea, vomiting, dizziness, musculoskeletal chest pain, and thrombocytopenia.

To report SUSPECTED ADVERSE REACTIONS, contact CorMedix Inc at 1-844-424-6345 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see the full Prescribing Information.

Schedule NTAP Claims Support